by BMJ Journals
Results of a single-site analysis suggest that despite emerging concern over the potential for secondary tumors and T-cell lymphoma following chimeric antigen receptor (CAR) T-cell infusion, such...
by ASTCT Talks and Oncology On the Go
In a special co-branded episode between Oncology On the Go and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program ASTCT Talks, Rahul Banerjee, MD,...
by AACR
Chimeric antigen receptor(CAR)-engineered natural killer (NK) cells designed with a CD28 costimulatory domain have superior anti-tumor efficacy and long-term cytotoxicity, research indicates.
by Alex Kadhim
Researchers from the Centre de Recherche Saint-Antoine (CRSA) at Sorbonne Université in France investigated the impact of early recovery of mucosal-associated invariant T (MAIT) cells and...
by NEJM
Results of a single-site analysis suggest that despite emerging concern over the potential for secondary tumors and T-cell lymphoma following chimeric antigen receptor (CAR) T-cell infusion, such...
by July 2024 Advocacy Update